Nova Leap Health Corp.

As of June 30, 2026, Nova Leap Health Corp. carries a market capitalization of 37.51M, placing it among publicly traded companies globally. Its enterprise value stands at 41.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nova Leap Health Corp.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Nova Leap Health Corp. has 87.31M shares outstanding.

As of June 30, 2026, Nova Leap Health Corp. trades at a trailing price-to-earnings ratio of 19.62. The price-to-sales ratio is 0.79, and the price-to-book ratio stands at 1.36.

As of June 30, 2026, Nova Leap Health Corp. trades at an EV/EBITDA multiple of 11.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.06 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Nova Leap Health Corp. trades at an EV/FCF ratio of 12.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 41.79M versus a market cap of 37.51M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nova Leap Health Corp. maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.94, indicating elevated leverage, while an interest coverage ratio of 7.33 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nova Leap Health Corp. posted a return on equity (ROE) of 7.07, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.45, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.95, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2026, Nova Leap Health Corp. recorded 729,441.30 in income tax expense. That works out to an effective tax rate of 27.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.64M, leaving 1.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Nova Leap Health Corp.'s stock has gained approximately 62.26% over the past 52 weeks. The 50-day moving average sits at 0.51, while the 200-day moving average is 0.38.

Over the twelve months ended June 30, 2026, Nova Leap Health Corp. generated 47.68M in revenue and converted that into 1.91M in net income, yielding earnings per share of 0.02. EBITDA reached 3.52M, while operating income came in at 2.45M.

As of June 30, 2026, Nova Leap Health Corp. holds 2.05M in cash and equivalents against 6.32M in total debt, resulting in a net debt position of 2.84M. Total book value stands at 27.56M, with working capital of -2.33M providing operational flexibility.

Nova Leap Health Corp. produced 2.91M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Nova Leap Health Corp. posted a gross margin of 39.92, reflecting its pricing power and cost economics. The operating margin of 5.14 and net profit margin of 4.01 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Nova Leap Health Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.71, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.21, meaning Nova Leap Health Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Nova Leap Health Corp. has an Altman Z-Score of 8.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.